Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis

PHASE3CompletedINTERVENTIONAL
Enrollment

1,950

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

January 25, 2023

Study Completion Date

January 25, 2023

Conditions
Post-ERCP Pancreatitis
Interventions
OTHER

Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement

OTHER

Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement

Trial Locations (20)

Unknown

Univesrity of Southern California, Los Angeles

University of Colorado, Denver

The Florida Hospital, Orlando

Emory University, Atlanta

Northwestern University, Chicago

University of Kansas, Kansas City

Johns Hopkins University, Baltimore

University of Michigan, Ann Arbor

Washington University, St Louis

Dartmouth University, Lebanon

Case Western Reserve University, Cleveland

The Ohio State University Wexner Medical Center, Columbus

Oregon Health & Science University, Portland

University of Pittsburgh, Pittsburgh

Medical University of South Carolina, Charleston

Vanderbilt University, Nashville

Virginia Mason Medical Center, Seattle

Medical College of Wisconsin, Milwaukee

University of Calgary, Calgary

McGill University, Montreal

All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Medical University of South Carolina

OTHER

NCT02476279 - Stent vs. Indomethacin for Preventing Post-ERCP Pancreatitis | Biotech Hunter | Biotech Hunter